Cargando…

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

PURPOSE: Napabucasin is a cancer stemness inhibitor that targets a number of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3). Phase 1/2 studies suggest tolerability and anti-tumor activity in various types of cancer; a Phase 3 study of napabucasin plus standa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawazoe, Akihito, Kuboki, Yasutoshi, Bando, Hideaki, Fukuoka, Shota, Kojima, Takashi, Naito, Yoichi, Iino, Shuichi, Yodo, Yasuhide, Doi, Toshihiko, Shitara, Kohei, Yoshino, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188713/ https://www.ncbi.nlm.nih.gov/pubmed/32236642 http://dx.doi.org/10.1007/s00280-020-04059-3

Ejemplares similares

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers
por: Noda, Naoto, et al.
Publicado: (2021)

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
por: Yukami, Hiroki, et al.
Publicado: (2022)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study
por: Naito, Yoichi, et al.
Publicado: (2018)

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2023)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)
por: Sunami, Kuniko, et al.
Publicado: (2018)

Next-generation sequencing and biomarkers for gastric cancer: what is the future?
por: Kawazoe, Akihito, et al.
Publicado: (2019)

The New Era of Immunotherapy in Gastric Cancer
por: Takei, Shogo, et al.
Publicado: (2022)

p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab
por: Fukuoka, Shota, et al.
Publicado: (2023)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
por: Doi, Toshihiko, et al.
Publicado: (2021)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
por: Tada, Yasuko, et al.
Publicado: (2018)

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience
por: Kubota, Yohei, et al.
Publicado: (2022)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

Repurposing Napabucasin as an Antimicrobial Agent against Oral Streptococcal Biofilms
por: Kuang, Xinyi, et al.
Publicado: (2020)

Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
por: Li, Ya, et al.
Publicado: (2020)

The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone
por: Shao, Zeyang, et al.
Publicado: (2023)

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis
por: Doi, Toshihiko, et al.
Publicado: (2017)

Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin
por: Zhang, Yiming, et al.
Publicado: (2016)

Corrigendum to “Repurposing Napabucasin as an Antimicrobial Agent against Oral Streptococcal Biofilms”
por: Kuang, Xinyi, et al.
Publicado: (2021)

Process Intensification of a Napabucasin Manufacturing Method Utilizing Microflow Chemistry
por: Usutani, Hirotsugu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jhr1e5li6183rrcdebl93ic1t7